NRXP - יחס חוב להיוון בספרים NRx Pharmaceuticals Inc.

NRx Pharmaceuticals focuses on developing therapies to combat suicidal depression while awaiting approval for the drug NRX-101. The company's revenues are based on the treatment of severe psychiatric disorders and viral lung injuries. The current debt-to-book capitalization ratio demonstrates financial stability, with the indicator reaching 0.00. The environmental profile is limited to compliance with laboratory standards for chemical waste disposal.

This indicator measures the ratio of borrowed funds relative to the market value of equity in real time. For NRx Pharmaceuticals (NRXP), this balance is critical for maintaining raw material warehouse reserves and uninterrupted drug supply chains. By analyzing the correlation between debt size and balance sheet equity, an investor can see the current level of financial leverage. A decrease in this metric minimizes bankruptcy risks. Stable dynamics confirm the high resilience of the company's capital structure.